Pro Medicus Advances Strategic Partnership with Echo IQ
Pro Medicus Limited (ASX: PME), a leading health imaging technology company, announced on 17 August 2026 that it has signed a Convertible Note debt and option agreement with Echo IQ Ltd (ASX: EIQ). The agreement marks the formal execution of the Heads of Agreement previously signed by the companies on 25 June 2026.
The latest development strengthens the commercial relationship between the two companies and provides a formal framework for the convertible note arrangement. While the announcement does not disclose the financial value, conversion terms or other detailed conditions of the agreement, the execution represents a further step in the collaboration between Pro Medicus and Echo IQ.
The agreement highlights Pro Medicus’ continued engagement in strategic opportunities within the health technology and medical imaging ecosystem. Further details regarding the arrangement may provide investors with additional insight into its potential financial and strategic implications.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au
x
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Start Your 7 Days Free Trial Now!
We use cookies to help us improve, promote, and protect our services.
By continuing to use this site, we assume you consent to this.
Read our
Privacy Policy
and
Terms & Conditions
Pro Medicus Advances Strategic Partnership with Echo IQ
Pro Medicus Limited (ASX: PME), a leading health imaging technology company, announced on 17 August 2026 that it has signed a Convertible Note debt and option agreement with Echo IQ Ltd (ASX: EIQ). The agreement marks the formal execution of the Heads of Agreement previously signed by the companies on 25 June 2026.
The latest development strengthens the commercial relationship between the two companies and provides a formal framework for the convertible note arrangement. While the announcement does not disclose the financial value, conversion terms or other detailed conditions of the agreement, the execution represents a further step in the collaboration between Pro Medicus and Echo IQ.
The agreement highlights Pro Medicus’ continued engagement in strategic opportunities within the health technology and medical imaging ecosystem. Further details regarding the arrangement may provide investors with additional insight into its potential financial and strategic implications.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au